(Q37025906)

17 August 2017

1 reference

title

Darunavir: in the treatment of HIV-1 infection (English)

1 reference

17 August 2017

1 reference

2

Caroline M Perry

1 reference

17 August 2017

Caroline Fenton

1

1 reference

17 August 2017

language of work or name

1 reference

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67

1 reference

17 August 2017

issue

18

1 reference

17 August 2017

page(s)

2791-2801

1 reference

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

17 August 2017

cites work

1 reference

12 December 2020

Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

12 December 2020

The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

1 reference

12 December 2020

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

1 reference

12 December 2020

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

1 reference

12 December 2020

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

1 reference

12 December 2020

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

Pharmacokinetic considerations for combining 2 protease inhibitors

1 reference

12 December 2020

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

1 reference

12 December 2020

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers

1 reference

12 December 2020

High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains

1 reference

12 December 2020

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial

1 reference

12 December 2020

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

1 reference

12 December 2020

Evolving therapeutic paradigms for HIV and HCV.

1 reference

12 December 2020

10.2165/00003495-200767180-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1038136415

0 references

1 reference